A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

NCT Number	NCT06119581
Lead Sponsor	Eli Lilly and Company
Conditions	Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Enrollment	1,264 participants
Start Date	2023-12-21
Primary Completion	2027-11 (estimated)
Study Completion	2031-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-20